AMARILLO, Texas, Jan. 4 /PRNewswire/ -- Amarillo Biosciences, Inc.
(Nasdaq: AMAR) today announced the appointment of Kathleen L. Kelleher as
Chief Operating Officer and Vice President of Business Development. Kelleher
comes to Amarillo Biosciences with 20 years of pharmaceutical and
biotechnology experience, and has held senior level positions in licensing and
business development, strategic planning, product planning and domestic and
European operations.
"Kathleen will oversee the daily operations and business development
activities for Amarillo Biosciences," said Joseph M. Cummins, President and
CEO of Amarillo Biosciences. In addition, Kelleher will work closely with
other members of the senior management team to help plan and manage the
Company's clinical trials.
Clinical trials are now being conducted in the United States and Canada.
The indications that are presently being studied include Sjogren's syndrome,
fibromyalgia and hepatitis B and C. Plans call for additional studies to be
initiated during 1999.
Prior to joining Amarillo Biosciences, Kelleher was Senior Director of
Licensing at G.D. Searle. Prior to joining Searle, she was responsible for
the worldwide business development and a key executive at Curative
Technologies and Vestar (now Nexstar), both early stage biotechnology
companies.
"We see this as an important step in our growth from a research-oriented
organization to a company focused on commercialization and partnering," Dr.
Cummins said.
Amarillo Biosciences, founded in 1984, is a world leader in the
development of oral interferon alpha as a treatment for a variety of
conditions including Sjogren's syndrome, fibromyalgia, opportunistic
infections in patients who are HIV positive, hepatitis B and hepatitis C.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the company's other product
candidates and other risks detailed from time to time in the company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Financial Business Risk Factors" of the company's Form 10-KSB for the year
ended Dec. 31, 1997."
SOURCE Amarillo Biosciences, Inc.
 back to top
Company News On-Call:
http://www.prnewswire.com/comp/118055.html or fax,
800-758-5804, ext. 118055
CONTACT:
Joseph M. Cummins, DVM, PhD, President and
CEO of Amarillo Biosciences Inc., 806-376-1741, or email,
amacell@arn.net
|
